Recent studies have highlighted the emerging role of newer drugs, such as sodium-glucose cotransporter 2 inhibitors and Glucagon-like Peptide 1 receptor agonists, in reducing the risk of AF recurrence [21,22]. Here, SLC5A2 is linked to atrial fibrillation.